化学
凝血酶
部分凝血活酶时间
凝血酶时间
部分
直接凝血酶抑制剂的发现与发展
酰化
凝结
共价键
凝血时间
组合化学
凝血酶原时间
抗凝剂
生物化学
药理学
立体化学
血小板
催化作用
有机化学
免疫学
医学
内科学
精神科
作者
Lukas Imberg,Alena I. Siutkina,Catharina Erbacher,Judith Schmidt,Darius F. Broekmans,Ruzanna A. Ovsepyan,Constantin G. Daniliuc,Ellen Gonçalves de Oliveira,Mateus Sá Magalhães Serafim,Anthony J. O’Donoghue,Thanigaimalai Pillaiyar,Mikhail A. Panteleev,Antti Poso,Svetlana A. Kalinina,Marcel Bermúdez,Katrin Nekipelov,Gerd Bendas,Uwe Kärst,Dmitrii V. Kalinin
标识
DOI:10.1021/acsptsci.4c00515
摘要
This study presents a novel series of N-acylated 1,2,4-triazol-5-amines and 1H-pyrazol-5-amines, featuring a pyrazin-2-yl moiety, developed as covalent inhibitors of thrombin. These compounds demonstrated potent inhibitory activity, with derivatives 13a and 13b achieving IC50 values as low as 0.7 and 0.8 nM, respectively. Mass-shift assays confirmed that these inhibitors covalently bind to the catalytic Ser195 of thrombin, leading to temporary inhibition of its activity through specific acylation. The anticoagulant efficacy of these compounds was validated in plasma coagulation assays, with selected derivatives extending coagulation times in both an activated partial thromboplastin time (aPTT) and prothrombin time (PT) test. Thrombin generation assays further demonstrated that compounds of this series effectively reduced thrombin generation without substantially prolonging clotting times, suggesting a lower risk of bleeding. Selected compounds also strongly inhibited cancer cell- and thrombin-induced platelet aggregation. These results indicate that acylated aminoazoles hold a promise as new anticoagulants.
科研通智能强力驱动
Strongly Powered by AbleSci AI